Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy shows impressive results in clinical trials. We conducted a meta-analysis based on the most recent data to systematically describe the efficacy and safety of anti-BCMA CAR T therapy for patients with relapsed or refractory multiple myeloma (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lina, Shen, Xuxing, Yu, Wenjun, Li, Jing, Zhang, Jue, Zhang, Run, Li, Jianyong, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409966/
https://www.ncbi.nlm.nih.gov/pubmed/34459681
http://dx.doi.org/10.1080/07853890.2021.1970218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409966/
https://www.ncbi.nlm.nih.gov/pubmed/34459681
http://dx.doi.org/10.1080/07853890.2021.1970218

Ejemplares similares